The journal retracts the 18 July 2017 article cited above.
During a recent review by the Creighton University Institutional Review Board that approved this study, it was found that the authors utilized and included some datasets that were not IRB-approved. Therefore, the study did not receive full ethics committee approval and is being withdrawn.
The authors concur with the retraction and sincerely regret any inconvenience this may have caused to the reviewers, editors, and readers of Frontiers in Oncology.
Summary
Keywords
Esophageal adenocarcinoma, Molecular diagnostics, Proteomics, targeted therapy, Targeted chemotherapy
Citation
Frontiers Editorial Office (2019) Retraction: Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting—Practice and Outcomes. Front. Oncol. 9:324. doi: 10.3389/fonc.2019.00324
Received
10 April 2019
Accepted
10 April 2019
Published
24 April 2019
Approved by
Giuseppe Giaccone, Georgetown University, United States
Volume
9 - 2019
Updates
Copyright
© 2019 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office editorial.office@frontiersin.org
This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.